N. Anthony Coles - 02 Jan 2026 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Reporting relationship: Director
Issuer ticker: REGN
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 16:11:54 UTC
Prior SEC filing: 06 Jan 2025
Source filing: View source filing
Reporting owner signature: By: Richard Gluckselig as attorney-in-fact For: N. Anthony Coles

Key filing fact

N. Anthony Coles filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 06 Jan 2026.

Key facts

This page summarizes N. Anthony Coles's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 16:11.

Change

Previous filing in this sequence was filed on 06 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001197018 Primary reporting owner

COLES N ANTHONY

Relationship: Director
Address: 777 OLD SAW MILL RIVER ROAD, TARRYTOWN
Signature: By: Richard Gluckselig as attorney-in-fact For: N. Anthony Coles
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

REGN transaction

Common Stock

Award

Transaction value: $0
Shares: +155
Change %: +9.9%
Price: $0.000000
Shares after: 1,714
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

REGN transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value: $0
Shares: +1,962
Change %
Price: $0.000000
Shares after: 1,962
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,962
Exercise price: $772.76
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

Footnote F2

On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.